Descriptive account of the first use of the LeVe CPAP System, a new frugal CPAP System, in adult patients with COVID-19 Pneumonitis in Uganda

Descriptive account of the first use of the LeVe CPAP System, a new frugal CPAP System, in adult patients with COVID-19 Pneumonitis in Uganda

Continuous positive airway pressure (CPAP) has been a key treatment modality for Coronavirus Disease 2019 (COVID-19) worldwide. Globally, the demand for CPAP outstripped the supply during the pandemic. The LeVe CPAP System was developed to provide respiratory support for treatment of COVID-19 and ta...

Full description

Saved in:
Bibliographic Details
Published in:Tropical medicine and health Vol. 51; no. 1; p. 42
Main Authors: Littlejohns, Anna, Please, Helen, Musasizi, Racheal, Murdoch, Stuart, Nampiina, Gorret, Waters, Ian, Birch, William Davis, de Boer, Gregory, Kapur, Nikil, Ambrozi, Tumwesigye, Carol, Ninsiima, Noel, Nakigudde, Parmar, Jiten, Culmer, Peter, Lawton, Tom, Namulema, Edith
Format: Journal Article
Language:English
Published: Japan BioMed Central 07-08-2023
BMC
Subjects:
Adults
Continuous positive airway pressure
Coronaviruses
COVID-19
CPAP
Critical care
Ethics
Hospitals
Intensive care
Intubation
LMIC
NIV
Pandemic
Pandemics
Respiratory failure
Statistical analysis
Sustainability
Ventilators
Uganda
COVID-19
CPAP
Global Health
Sustainability
LMIC
Pandemic
NIV
Anaesthetics
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Continuous positive airway pressure (CPAP) has been a key treatment modality for Coronavirus Disease 2019 (COVID-19) worldwide. Globally, the demand for CPAP outstripped the supply during the pandemic. The LeVe CPAP System was developed to provide respiratory support for treatment of COVID-19 and tailored for use in low- and middle-income country (LMIC) settings. Prior to formal trial approval, received in November 2021, these devices were used in extremis to support critically unwell adult patients requiring non-invasive ventilatory support. This is a retrospective descriptive review of adult patients with COVID-19 pneumonitis, who were treated with advanced respiratory support (CPAP and/or high-flow nasal oxygen, HFNO) at Mengo Hospital, Uganda. Patients were treated with the LeVe CPAP System, Elisa CPAP and/or AIRVO™ HFNO. Treatment was escalated per standard local protocols for respiratory failure, and CPAP was the maximum respiratory support available. Data were collected on patient characteristics, length of time of treatment, clinical outcome, and any adverse events. Overall 333 patients were identified as COVID-19 positive, 44 received CPAP ± HFNO of which 43 were included in the study. The median age was 58 years (range 28-91 years) and 58% were female. The median duration of advanced respiratory support was 7 days (range 1-18 days). Overall (all device) mortality was 49% and this was similar between those started on the LeVe CPAP System and those started non-LeVe CPAP System devices (50% vs 47%). The LeVe CPAP system was the most used CPAP device during the pandemic, bringing the hospital's number of available HFNO/CPAP devices from two to 14. They were a critical resource for providing respiratory support to the sickest group of patients when no alternative devices were available. The devices appear to be safe and well-tolerated with no serious adverse events recorded. This study is unable to assess the efficacy of the LeVe CPAP System; therefore, formal comparative studies are required to inform further use.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:1348-8945
1349-4147
1349-4147
DOI:10.1186/s41182-023-00533-9